Literature DB >> 17317860

Expression of oncogenic K-ras from its endogenous promoter leads to a partial block of erythroid differentiation and hyperactivation of cytokine-dependent signaling pathways.

Jing Zhang1, Yangang Liu, Caroline Beard, David A Tuveson, Rudolf Jaenisch, Tyler E Jacks, Harvey F Lodish.   

Abstract

When overexpressed in primary erythroid progenitors, oncogenic Ras leads to the constitutive activation of its downstream signaling pathways, severe block of terminal erythroid differentiation, and cytokine-independent growth of primary erythroid progenitors. However, whether high-level expression of oncogenic Ras is required for these phenotypes is unknown. To address this issue, we expressed oncogenic K-ras (K-ras(G12D)) from its endogenous promoter using a tetracycline-inducible system. We show that endogenous K-ras(G12D) leads to a partial block of terminal erythroid differentiation in vivo. In contrast to results obtained when oncogenic Ras was overexpressed from retroviral vectors, endogenous levels of K-ras(G12D) fail to constitutively activate but rather hyperactivate cytokine-dependent signaling pathways, including Stat5, Akt, and p44/42 MAPK, in primary erythroid progenitors. This explains previous observations that hematopoietic progenitors expressing endogenous K-ras(G12D) display hypersensitivity to cytokine stimulation in various colony assays. Our results support efforts to modulate Ras signaling for treating hematopoietic malignancies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17317860      PMCID: PMC1890843          DOI: 10.1182/blood-2006-09-047050

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

1.  Epiblast-restricted Cre expression in MORE mice: a tool to distinguish embryonic vs. extra-embryonic gene function.

Authors:  M D Tallquist; P Soriano
Journal:  Genesis       Date:  2000-02       Impact factor: 2.487

2.  Extra-embryonic function of Rb is essential for embryonic development and viability.

Authors:  Lizhao Wu; Alain de Bruin; Harold I Saavedra; Maja Starovic; Anthony Trimboli; Ying Yang; Jana Opavska; Pamela Wilson; John C Thompson; Michael C Ostrowski; Thomas J Rosol; Laura A Woollett; Michael Weinstein; James C Cross; Michael L Robinson; Gustavo Leone
Journal:  Nature       Date:  2003-02-27       Impact factor: 49.962

3.  Stringent doxycycline dependent control of CRE recombinase in vivo.

Authors:  Kai Schönig; Frieder Schwenk; Klaus Rajewsky; Hermann Bujard
Journal:  Nucleic Acids Res       Date:  2002-12-01       Impact factor: 16.971

4.  Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects.

Authors:  David A Tuveson; Alice T Shaw; Nicholas A Willis; Daniel P Silver; Erica L Jackson; Sandy Chang; Kim L Mercer; Rebecca Grochow; Hanno Hock; Denise Crowley; Sunil R Hingorani; Tal Zaks; Catrina King; Michael A Jacobetz; Lifu Wang; Roderick T Bronson; Stuart H Orkin; Ronald A DePinho; Tyler Jacks
Journal:  Cancer Cell       Date:  2004-04       Impact factor: 31.743

5.  Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo.

Authors:  Benjamin S Braun; Joehleen A Archard; Jessica A G Van Ziffle; David A Tuveson; Tyler E Jacks; Kevin Shannon
Journal:  Blood       Date:  2006-05-23       Impact factor: 22.113

6.  Identification of endoglin as a functional marker that defines long-term repopulating hematopoietic stem cells.

Authors:  Chang-Zheng Chen; Min Li; David de Graaf; Stefano Monti; Berthold Göttgens; Maria-Jose Sanchez; Eric S Lander; Todd R Golub; Anthony R Green; Harvey F Lodish
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-15       Impact factor: 11.205

7.  Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.

Authors:  Iris T Chan; Jeffery L Kutok; Ifor R Williams; Sarah Cohen; Lauren Kelly; Hirokazu Shigematsu; Leisa Johnson; Koichi Akashi; David A Tuveson; Tyler Jacks; D Gary Gilliland
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

8.  Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.

Authors:  Benjamin S Braun; David A Tuveson; Namie Kong; Doan T Le; Scott C Kogan; Jacob Rozmus; Michelle M Le Beau; Tyler E Jacks; Kevin M Shannon
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-29       Impact factor: 11.205

9.  Role of Ras signaling in erythroid differentiation of mouse fetal liver cells: functional analysis by a flow cytometry-based novel culture system.

Authors:  Jing Zhang; Merav Socolovsky; Alec W Gross; Harvey F Lodish
Journal:  Blood       Date:  2003-08-07       Impact factor: 22.113

10.  Constitutive activation of the MEK/ERK pathway mediates all effects of oncogenic H-ras expression in primary erythroid progenitors.

Authors:  Jing Zhang; Harvey F Lodish
Journal:  Blood       Date:  2004-05-27       Impact factor: 22.113

View more
  18 in total

1.  Defective erythroid differentiation in miR-451 mutant mice mediated by 14-3-3zeta.

Authors:  David M Patrick; Cheng C Zhang; Ye Tao; Huiyu Yao; Xiaoxia Qi; Robert J Schwartz; Lily Jun-Shen Huang; Eric N Olson
Journal:  Genes Dev       Date:  2010-08-01       Impact factor: 11.361

Review 2.  Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development.

Authors:  Eva Chung; Motonari Kondo
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

3.  Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.

Authors:  Qing Li; Kevin M Haigis; Andrew McDaniel; Emily Harding-Theobald; Scott C Kogan; Keiko Akagi; Jasmine C Y Wong; Benjamin S Braun; Linda Wolff; Tyler Jacks; Kevin Shannon
Journal:  Blood       Date:  2010-12-16       Impact factor: 22.113

4.  KRAS(G12V) enhances proliferation and initiates myelomonocytic differentiation in human stem/progenitor cells via intrinsic and extrinsic pathways.

Authors:  Szabolcs Fatrai; Djoke van Gosliga; Lina Han; Simon M G J Daenen; Edo Vellenga; Jan Jacob Schuringa
Journal:  J Biol Chem       Date:  2010-12-17       Impact factor: 5.157

Review 5.  Emerging EPO and EPO receptor regulators and signal transducers.

Authors:  David Kuhrt; Don M Wojchowski
Journal:  Blood       Date:  2015-04-17       Impact factor: 22.113

6.  Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.

Authors:  Gordon Chan; Demetrios Kalaitzidis; Tatiana Usenko; Jeffery L Kutok; Wentian Yang; M Golam Mohi; Benjamin G Neel
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

7.  MASL1 induces erythroid differentiation in human erythropoietin-dependent CD34+ cells through the Raf/MEK/ERK pathway.

Authors:  Chutima Kumkhaek; Wulin Aerbajinai; Wenli Liu; Jianqiong Zhu; Naoya Uchida; Roger Kurlander; Matthew M Hsieh; John F Tisdale; Griffin P Rodgers
Journal:  Blood       Date:  2013-01-17       Impact factor: 22.113

8.  RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia.

Authors:  Won-Il Kim; Ilze Matise; Miechaleen D Diers; David A Largaespada
Journal:  Blood       Date:  2008-10-24       Impact factor: 22.113

9.  K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors.

Authors:  Thomas Kindler; Melanie G Cornejo; Claudia Scholl; Jianing Liu; Dena S Leeman; J Erika Haydu; Stefan Fröhling; Benjamin H Lee; D Gary Gilliland
Journal:  Blood       Date:  2008-07-28       Impact factor: 22.113

10.  A Synthetic Lethal Interaction between Glutathione Synthesis and Mitochondrial Reactive Oxygen Species Provides a Tumor-Specific Vulnerability Dependent on STAT3.

Authors:  Daniel J Garama; Tiffany J Harris; Christine L White; Fernando J Rossello; Maher Abdul-Hay; Daniel J Gough; David E Levy
Journal:  Mol Cell Biol       Date:  2015-08-17       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.